Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Change in Accured Expenses (2016 - 2025)

Moleculin Biotech's Change in Accured Expenses history spans 10 years, with the latest figure at $218000.0 for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $218000.0 for Q4 2025, down 22.42% from a year ago — trailing twelve months through Dec 2025 was $17000.0 (up 101.53% YoY), and the annual figure for FY2025 was $17000.0, up 101.53%.
  • Change in Accured Expenses for Q4 2025 was $218000.0 at Moleculin Biotech, up from -$549000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $2.4 million in Q4 2023 to a low of -$1.1 million in Q1 2024.
  • The 5-year median for Change in Accured Expenses is $75000.0 (2022), against an average of $56100.0.
  • Peak annual rise in Change in Accured Expenses hit 3330.67% in 2023, while the deepest fall reached 1611.36% in 2023.
  • Year by year, Change in Accured Expenses stood at $11000.0 in 2021, then crashed by 781.82% to -$75000.0 in 2022, then surged by 3330.67% to $2.4 million in 2023, then crashed by 88.4% to $281000.0 in 2024, then dropped by 22.42% to $218000.0 in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at $218000.0, -$549000.0, and -$390000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.